DT&CRO CO., Ltd.
Financials
Valuation Metrics
DT&CRO CO., Ltd.'s Market Cap is ₩242B. At end of 2025 it was ₩331B. Ranked #2137 of 2,412 in KR market (top 89%), #1384 of 1,632 on KOSDAQ (top 85%), #219 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 95%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 24.17B KRW | KR#2,137/2,412 Sec#219/231 |
| Revenue | 49.00B KRW | KR#1,802/2,412 Sec#124/231 |
| Net Income | -17.09B KRW | KR—/2,412 Sec—/231 |
| Total Assets | 90.28B KRW | KR#1,856/2,412 Sec#149/231 |
| Net Assets | 7.21B KRW | KR#2,378/2,412 Sec#226/231 |
| Employees | 333 | KR#724/2,412 Sec#63/231 |
| Value | ||
| P/B | 3.35x | KR#2,186/2,412 Sec#182/231 |
| P/S | 0.49x | KR#1,002/2,412 Sec#47/231 |
| FCF Yield | -51.26% | KR—/2,412 Sec—/231 |
| Profitability | ||
| ROA | -18.93% | KR#2,228/2,412 Sec#172/231 |
| Op. Margin | -21.29% | KR#2,126/2,412 Sec#148/231 |
| Revenue Growth | 15.85% | KR#656/2,412 Sec#62/231 |
| Earnings Growth | -497.61% | KR#1,298/2,412 Sec#90/231 |
| Financial Health | ||
| Debt Ratio | 1152.42% | KR#2,361/2,412 Sec#227/231 |
| Total Debt | 50.05B KRW | KR#1,003/2,412 Sec#70/231 |
| FCF | -12.39B KRW | KR#1,764/2,412 Sec#158/231 |
| Cash | 1.57B KRW | KR#2,283/2,412 Sec#217/231 |
| Current Ratio | 0.38x | KR#2,185/2,412 Sec#212/231 |
| Performance | ||
| 1Y Return | -33.77% | KR#1,466/2,412 Sec#113/231 |
| 1M Return | -4.16% | KR#81/2,412 Sec#12/231 |
| From 52W High | -54.05% | KR#1,225/2,412 Sec#99/231 |
| 1Y MDD | -61.28% | KR#1,533/2,412 Sec#124/231 |
| Trading | ||
| Volume | 17,508 shares | KR#1,107/2,412 Sec#120/231 |
| Trading Value | 32.7M KRW | KR#1,534/2,412 Sec#165/231 |
| Foreign Own. | 1.27% | KR#1,922/2,412 Sec#187/231 |
| Per Share | ||
| EPS | -1,337 KRW | KR—/2,412 Sec—/231 |
| BPS | 564 KRW | KR#2,369/2,412 Sec#225/231 |
Company Info
Established in 2017 as a CRO providing non-clinical and clinical trial services across various fields, DT&CRO listed on KOSDAQ in 2022. The company conducts non-clinical tests like efficacy, pharmacokinetic, and GLP toxicology studies, as well as bioequivalence and clinical trials, and signed an FDA IND consulting MOU with a US research company in 2024. DT&CRO offers one-stop services from non-clinical to clinical and regulatory approval, emerging as a CRO industry leader through initiatives like AI-powered smart clinical trial platform development. DT&CRO is headquartered in Yongin-si, Gyeonggi-do.